ArticleOncoTargets and therapy2026

Design and Engineering of Recombinant Oncolytic Adenoviruses Expressing an Anti-EpCAM/Anti-CD3 BiTE for Targeted Immunotherapy of A549 Lung Cancer Cells.

Ensieh Taheri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.